A Credit Suisse analyst upgraded shares of Walgreen Co. on Tuesday, saying the drugstore chain should have a strong year in 2012. Get the full story »
Inside these posts: Walgreens
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Walgreen Co. shares soar on earnings news
Shares of Walgreen Co. surged more than 7 percent in midday trade after the company reported record quarterly earnings and sales for the first quarter of fiscal year 2011. Get the full story »
Walgreens, ‘Dr. Oz Show’ encourage flu shots
Deerfield-based Walgreens and the syndicated “The Dr. Oz Show” from Oprah Winfrey’s Harpo Productions are teaming on a multi-platform campaign to encourage flu vaccinations.
Walgreen July same-store sales miss estimates
U.S. drugstore chain Walgreen Co. reported a weaker-than-expected rise in July same-store sales, hurt by sales of lower-priced generic drugs and decreased sales of flu remedies.
Sales at drugstores open at least a year rose 0.4 percent compared to July 2009, less than the 1.6 percent expected by analysts, according to Thomson Reuters data. Get the full story »
Walgreens: We can make up for lost CVS business
From Bloomberg | Greg Wasson, the CEO of Walgreen Co., says his company can make up for the loss of business with CVS Caremark Corp. by expanding corporate health-care clinics and adjusting costs in some markets.
Get the full story: businessweek.com.
Walgreens won’t sell genetic test kits amid controversy
By Bruce Japsen and Sandra M. Jones | Walgreen Co. reversed a decision to carry genetic test kits in its stores after the U.S. Food and Drug Administration began looking into the supplier.
The Deerfield-based drugstore had planned to begin stocking its shelves with the Pathway Genomics home test kit on Friday, as reported by the Tribune yesterday. Walgreens’ decision was announced within hours after the FDA released an enforcement letter sent to San Diego-based Pathway giving it 15 days to respond to the agency’s request for information regarding its controversial genetic home test kit.
FDA gives maker of gene test kit a deadline to respond
By Bruce Japsen and Sandra M. Jones | The U.S. Food and Drug Administration has given San Diego-based Pathway Genomics 15 days to respond to the agency’s request for information regarding its controversial genetic home test kit.
In a letter released this evening, FDA Deputy Director for Patient Safety and Product Quality James Woods said the agency has been “unable to identify any Food and Drug Administration clearance or approval number” for the product.
